Compare Johnson & Johnson (JNJ) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Sprott Uranium Miners ETF — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Sprott Uranium Miners ETF trades at $46.5 (market cap $1.87B). The key difference: Johnson & Johnson is far larger — about 330.5× Sprott Uranium Miners ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Sprott Uranium Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Sprott Uranium Miners ETF for 61 Days on average.
| JNJ | URNM | |
|---|---|---|
Market Cap | $618.09B | $1.87B |
Volume | 6,050,983 | 1,586,926 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $278.43 | $83.99 |
52-Week Low | $186.00 | $46.09 |
Typical Hold Time | 129 Days | 61 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
URNM (Sprott Uranium Miners ETF) trades at $46.09, down 3.72% today amid bearish technical signals. The ETF shows strong fundamental support from uranium's supply-demand imbalance and growing AI energy demand. Recent news highlights nuclear energy's resurgence, with uranium prices rising 21.25% over the past year according to Sprott Asset Management data from August 2026.
Long-term outlook remains positive due to structural uranium deficits and government nuclear investments, but short-term technical weakness and ETF volatility present near-term risks. The convergence of AI power demand and nuclear expansion creates substantial growth potential for uranium miners over the next decade.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
